Neosine (Inosine Pranobex)

Inosine Pranobex, the active ingredient in Neosine, is an immunomodulator presented as an oral formulation for oral use. It is employed to support the immune response in viral infections and is indicated for use in adults and children when prescribed by a healthcare professional. The compound modulates host defenses and exhibits broad‑spectrum antiviral activity, making it a therapeutic option in certain acute viral illnesses.

GNH USA supplies Neosine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neosine (Inosine Pranobex) is used as an immunostimulant in the management of viral infections.

- Herpes simplex infection: reduces lesion duration and viral shedding. - Influenza virus infection: alleviates symptoms and may shorten disease course. - Respiratory viral infections: supports immune response and may reduce severity. - Human papillomavirus (HPV) warts: promotes clearance in some cases. - Cytomegalovirus infection in immunocompromised patients: provides adjunctive immune support.

Adverse reactions may occur with Neosine use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal discomfort: occasional cramps or pain. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty, swelling, or hives. - Liver dysfunction: elevated transaminases or jaundice. - Hematologic disorders: leukopenia, thrombocytopenia, or anemia.

Neosine should be used with appropriate clinical oversight. - Assess renal and hepatic function before initiating: monitor laboratory values periodically. - Avoid use in known hypersensitivity to inosine pranobex: discontinue if reaction occurs. - Use with caution in immunocompromised patients: evaluate risk‑benefit balance. - Monitor for signs of hematologic abnormalities: perform complete blood count as indicated. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Potential drug interactions should be reviewed before therapy.

Major Interactions (Avoid): - Concurrent use with immunosuppressants: may reduce antiviral efficacy. - Combination with live vaccines: risk of altered immune response. - Co‑administration with hepatotoxic drugs: increased risk of liver injury.

Moderate Interactions (Monitor Closely): - Use with anticoagulants: monitor bleeding parameters. - Combination with other antiviral agents: assess additive toxicity. - Use with CYP450 substrates: possible metabolic interaction requiring dose adjustment.